Compare Procter & Gamble Co (PG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Zoetis Inc — how do they compare? Procter & Gamble Co trades at $143.2 (market cap $331.31B), while Zoetis Inc trades at $73.88 (market cap $30.29B). The key difference: Procter & Gamble Co is far larger — about 10.9× Zoetis Inc's market cap, and Procter & Gamble Co pays the higher dividend (3.05%). Which is the better fit depends on your goals.
| PG | ZTS | |
|---|---|---|
Market Cap | $331.31B | $30.29B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $150.61 |
52-Week Low | $138.10 | $71.91 |
Enterprise Value | $357.15B | $37.86B |
Dividend Yield | 3.05% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $145.59, down 0.57% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $1.89. Fundamentals show robust profitability, including an 18.44% net income margin and 30.13% ROE, though valuation ratios like P/E of 21.55 and P/S of 3.97 are at premiums. Recent news highlights PG's dividend reliability and supply chain enhancements amid market volatility.
The outlook for PG is mixed, with analyst consensus favoring a buy rating (50.94%) and a $162.50 price target suggesting upside. Opportunities include steady dividend growth and operational efficiency gains, but risks involve premium valuation pressures and soft demand concerns. Investors should weigh strong cash flow against potential macroeconomic headwinds affecting consumer spending.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
